PulseBio Secures Tens of Millions in Pre-A Financing to Accelerate Commercialization of Innovative Clinical Mass Spectrometry Solutions

VCBeat has learned at the earliest opportunity,Shanghai MASSWILL Biotechnology Co., Ltd. (hereinafter referred to as “MASSWILL”) announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by Zhangke Lingyi, with Tellgen Corporation (hereinafter referred to as “Tellgen”) participating as a follow-on investor.The proceeds from this financing round will be used to accelerate the clinical translation, upgrading, and regulatory filing of the company’s innovative products, as well as to expand channel distribution and advance other commercialization initiatives.

MASSWILL, established in 2022, is an innovative high-tech biotechnology enterprise jointly founded by Tellgen Corporation (Stock Code: 300642) and a team of highly experienced R&D, management, and marketing professionals from the industry.

MASSWILL is committed to overcoming clinical challenges and meeting the diagnostic and therapeutic needs of diseases. Focusing on cardiovascular health, maternal and child health, and chronic disease management, it gathers top global scientific research resources and utilizes mass spectrometry and multi-omics analysis technologies to build a precision medicine technology platform. Currently, MASSWILL has successfully launched over one hundred testing items, covering multiple fields including cardiovascular diseases, chronic disease management, maternal and child health, oncology, infectious diseases, and mental disorders.

MASSWILL offers a comprehensive product line covering the entire workflow of mass spectrometry testing. Among these, “Wuxinpu” is a novel combination of small-molecule biomarkers derived from metabolomics research by MASSWILL, providing a more robust scientific basis for the clinical management of individuals at high risk for cardiovascular diseases. “Maijike” is a fully automated sample processing system specifically designed to address pain points in pre-analytical mass spectrometry workflows. Featuring high levels of automation and high throughput, it significantly enhances the efficiency of clinical testing and facilitates the widespread adoption of clinical mass spectrometry products.

Since its establishment, MASSWILL has applied for and obtained eight national invention patents. In 2022, it was shortlisted among the top 13 finalists for the 4th Qipu Awards for Innovation in Medical In Vitro Diagnostics (IVD). It was also ranked among the “Top 10 Qipu Seeds for IVD Innovation 2023.” In 2023, the company secured a project grant under the Biomedical Technology Support Special Program of Shanghai’s “Science and Technology Innovation Action Plan.”

Zhangke Lingyi Founding Partner Yu Xiaoyongstated: “Liquid chromatography-tandem mass spectrometry (LC-MS/MS) holds immense potential in the field of precision diagnostics due to its unique advantages. However, its clinical application still faces many pain points that need to be addressed. We have been closely monitoring this sector and remain optimistic about its development prospects. The MASSWILL team is dedicated to product research and development as well as innovation in the field of clinical mass spectrometry. By continuously refining its technologies and products to meet the actual needs of clinical customers, it has successfully localized the outcomes of international clinical research projects. All members of the MASSWILL team possess over ten years of professional experience in R&D and commercialization within the industry, combining capabilities in both reagent kit development and customized hardware solutions for clinical use. We look forward to MASSWILL launching more solutions tailored to clinical demands, leading the mass spectrometry testing market, and driving the high-quality development of the precision diagnostics industry.”

Niu Zhengxiang, General Manager of MASSWILLstated: “We are deeply honored to have garnered the favor of investment institutions, and we thank our investors for their recognition and support of MASSWILL. We will fully leverage the funds from this financing round to accelerate R&D and product upgrades, regulatory filing, channel expansion, and clinical market promotion, thereby delivering value to our investors. We remain fully committed to addressing pain points in clinical mass spectrometry, making mass spectrometry testing products more diverse and accessible, streamlining testing processes for greater convenience and efficiency, and ensuring more precise and reliable test results.”